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Nicholas Kiraly1,2*, Aliu Balde1, Ida Marie Lisse1, Helle Brander Eriksen1,3, Peter Aaby1,3 and Christine Stabell Benn1,3Abstract
Background: The World Health Organization recommends high-dose vitamin A supplementation (VAS) for children
above six months of age in low-income countries. VAS has been associated with up-regulation of the Th2 response.
We aimed to determine if VAS is associated with atopy in childhood.
Methods: Infants in Guinea-Bissau were randomly allocated VAS or placebo, either at six and nine months of age,
or only at nine months of age. At six months of age, children were furthermore randomized to measles vaccine or
inactivated polio vaccine. At nine months of age all children received measles vaccine. Children were revisited
seven years later and skin prick testing was performed. Atopy was defined as a skin prick reaction ≥3 mm.
Results: 40 of 263 children (15%) were atopic. Overall VAS had no significant effect on the risk of atopy (Prevalence
Ratio 1.23; 95% CI 0.69-2.18). The Prevalence Ratio was 1.60 (0.66-3.90) for males and 1.00 (0.46-2.15) for females.
Conclusions: There was no significant effect of VAS in infancy on atopy later in childhood. The role of infant VAS in
the development of atopy is still unclear.
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The World Health Organization (WHO) currently recom-
mends high-dose vitamin A supplementation (VAS) for
children over six months of age in countries with high
prevalence of vitamin A deficiency. Vitamin A and its de-
rivatives are potent immune modulators and while dietary
vitamin A intake has been associated with protection from
asthma in some epidemiological studies [1], there is
laboratory evidence that high-dose VAS might increase
atopic asthma [2,3].
In the only human study of VAS and atopy, high-dose
neonatal VAS increased odds of atopy almost three-fold
[4]. This effect was found at age three to nine years,
although neonatal VAS had no effect on serum vitamin A* Correspondence: nicholas.kiraly@mcri.edu.au
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reproduction in any medium, provided the orlevels at six weeks of age [5]. Thus, VAS given early in life
may have a long-lasting imprinting effect on the develop-
ing immune system.
Here we report long-term follow-up of a randomized
trial of VAS given with vaccines after six months of age
[6]. The trial was originally performed to assess the adju-
vant effect of VAS on measles-specific antibodies. The aim
of the present follow-up study was to determine if VAS
given with vaccinations after six months of age is associ-
ated with atopy in childhood.Methods
The Bandim Health Project performed a randomized,
double-blind, placebo-controlled trial of VAS between
1993 and 1995 in Bissau, Guinea-Bissau, as previously de-
scribed [6,7]. Children approaching six months of age
were visited at home in Belem and Mindara, areas coveredtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Surveillance System. Children who were <7.5 months of
age were eligible for random allocation to an extra vaccine
(either measles vaccine or inactivated poliomyelitis vaccine
(IPV)), together with VAS or placebo (Figure 1). At nine
months of age they were revisited and given a dose of
measles vaccine irrespective of their original vaccination
group, along with VAS or placebo as they had received at
six months. Those >7.5 months of age at the first visit
were not eligible for the extra vaccine but were given the
usual dose of measles vaccine due at nine months of age,
and were randomly allocated to VAS or placebo. VAS
or placebo was given orally as 100 000 IU vitamin A or
placebo in 1 mL vegetable oil with 40 IU vitamin E.
All 462 children enrolled in the original trial were eligible
for follow-up. Children were revisited at home between
May and August 2000 and verbal consent obtained from a
parent or guardian. Verbal consent was considered appro-
priate at the time of the study in this population with a
low literacy rate and was approved by the Guinea-Bissau
Ministry of Public Health. Anthropometry and environ-
mental data was collected. Skin prick testing was performed
using four aero-allergens (dermatophagoides pterynissinus,
d. farinae, blomia tropicalis, and blatella germanica) with
positive and negative controls. All tests were performed by
Dr. Aliu Balde. Data were excluded from analysis if there
was no response to the positive control. Atopy was defined
as a positive test to any allergen ≥3 mm after subtracting
the negative control.
Groups were compared using Chi squared or Kruskal-
Wallis tests. The effect of VAS was analyzed using Poisson
regression providing prevalence ratios (PR) with adjust-
ment for sex and age at follow-up. Statistical analyses were
performed using Stata 11. The study received ethical ap-
proval from the Ministry of Public Health, Guinea-Bissau.Placebo
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Figure 1 Study profile. VAS = Vitamin A supplementation.Results
Of the 462 children enrolled in the original trial, 274 (59%)
had skin prick testing performed at follow-up. 170 children
received an extra vaccine and therefore also received two
doses of VAS or placebo (Figure 1). 137 children received
VAS and 137 children received placebo. There were no sig-
nificant differences between the VAS and placebo groups at
enrolment in background demography or anthropometry
(Table 1).
10 children had missing skin prick test data and one
child did not respond to the positive control. Of the 263
children for whom valid skin prick tests were available, 40
(15%) were atopic. 19 had reactions to d. pterynissinus, 12
to d. farinae, 21 to b. tropicalis, and three to b. germanica.
Overall, VAS had no significant effect on atopy (PR
1.23; 95% CI 0.69-2.18, Table 1). The PR was 1.60 (0.66-
3.90) for males and 1.00 (0.46-2.15) for females (p = 0.43
for the same effect VAS in males and females). There
were no differences in the effect of VAS on atopy be-
tween groups receiving measles vaccine, IPV or no vac-
cine at 6 months of age (data not shown). Compared to
placebo, the PR of atopy associated with one dose of
VAS was 1.18 (0.45-3.15) and with two doses of VAS
was 1.22 (0.60-2.49; p = 0.96 for the same effect of one
and two doses of VAS).
Discussion and conclusions
This study is the first to evaluate the effect on atopy of
the WHO recommended policy of providing VAS to-
gether with vaccinations after six months of age. VAS
had no significant effect on atopy later in childhood.
We recently reported a 2.8-fold increase in atopy associ-
ated withVAS when given at birth [4]. In the present study
using a higher dose of VAS (100 000 IU versus 25 000 IU
in [4]), we found no significant effect of VAS given afterPlacebo
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Table 1 Demographics, anthropometry and prevalence of atopy according to randomization group
VAS (n = 137) Placebo (n = 137) P value or PR (95% CI)
At enrolment
Age (days) 200 (183–294) n = 137 198 (183–301) n = 137 0.93
Weight (kg) 7.1 (6.1-8.7) n = 88 7.5 (5.9-8.8) n = 79 0.35
MUAC (mm) 144 (126–160) n = 86 144 (130–166) n = 80 0.99
Breastfeeding 86/94 (91%) 80/90 (89%) 0.55
DTP3 vaccinated 84/137 (61%) 95/137 (69%) 0.16
At follow up
Age (years) 7.4 (7.0-7.7) n = 137 7.4 (7.0-7.7) n = 137 0.72
Weight (kg) 20.0 (17.0-24.0) n = 136 20.5 (17.0-23.5) n = 137 0.78
Height (cm) 119 (112–126) n = 137 118 (111–125) n = 137 0.46
MUAC (mm) 166 (150–184) n = 137 166 (152–180) n = 137 0.77
BCG scar 105/132 (80%) 110/131 (84%) 0.35
Pig at the house 43/134 (32%) 47/133 (35%) 0.57
Atopy in all children (n = 263) 22/131 (17%) 18/132 (14%) 1.23 (0.69-2.18)
Atopy stratified by sex
Boys (n = 135) 11/67 (16%) 7/68 (10%) 1.60 (0.66-3.90)
Girls (n = 128) 11/64 (17%) 11/64 (17%) 1.00 (0.46-2.15)
VAS = vitamin A supplementation; PR = prevalence ratio adjusted for age and sex; MUAC =mid-upper arm circumference; DTP3 = 3rd dose of diphtheria-tetanus-
whole cell pertussis vaccine due at 14 weeks of age.
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these differing results. It may be that the immune system
is most susceptible to an imprinting effect from exposure
in the immediate post-natal period [8]. Alternatively, it
may be due to co-administration with, or subsequent ad-
ministration of, vaccinations. In our previous work, the
harmful effect of VAS occurred largely in those who re-
ceived BCG vaccination [4], whereas in the current work
children received either measles vaccine or IPV. We have
previously observed that VAS interacts with vaccines in
relation to overall mortality [9].
Any effect of high-dose VAS in infancy on atopy much
later in childhood would likely be unrelated to current
vitamin A levels, which are unaffected by VAS beyond six
weeks [5]. A number of animal studies have found positive
associations between high-dose VAS and atopic pheno-
types at the time of supplementation [2,3] but there are no
laboratory studies examining the effect of high-dose VAS
in infancy on atopy much later in life. Although we found
no significant effect of VAS in infancy on atopy in child-
hood in the present study, it is plausible that VAS could
have long-term effects on atopy as activation of RAR/RXR
by all-trans retinoic acid has the ability to activate gene
transcription and cause stable epigenetic changes in mul-
tiple immune cell linages [10].
We found a non-significant increase in atopy in the VAS
versus placebo group. This study was limited by a small
sample size and low prevalence of atopy, which may have
caused a modest effect of VAS to be undetectable. Inconclusion, the role of VAS in the development of atopy is
still unclear, but with several new neonatal vitamin A trials
ongoing [11], there are possibilities for testing it further.
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